Zenith Energy raises £2.1 million, but warrants add to the dilution question

What has Zenith Energy announced?

Zenith Energy has completed a private placement with existing institutional investors in Norway, raising approximately £2.116 million through the issue of 50 million new common shares.

The placing price was NOK 0.55 per share, equivalent to a discount of approximately 0.36% to Zenith's closing price on Euronext Growth Oslo on 20 July 2026.

That is a very small discount for an equity fundraising. However, the deal also includes 50 million warrants on a one-for-one basis, potentially creating a second round of dilution if they are exercised.

The proceeds are earmarked for Zenith's new biogas project, its solar portfolio, legal expenses connected with international arbitration proceedings and general working capital.

The key financing figures

Financing detail	Amount
Gross amount raised	Approximately £2.116 million
Norwegian krone equivalent	Approximately NOK 27.5 million
US dollar equivalent	Approximately US$2.848 million
New shares issued	50 million
Subscription price	NOK 0.55 per share
Discount to previous Oslo close	Approximately 0.36%
Shares following admission	764,756,457
Warrants issued	50 million
Warrant exercise price	NOK 0.675
Approximate sterling exercise price	£0.0519
Warrant duration	Two years

The 50 million new shares represent approximately 6.5% of Zenith's enlarged share capital following admission. Put another way, the share count has increased by roughly 7.0% compared with the number in issue before the financing.

That is meaningful dilution, even though the subscription price was close to the previous market price.

Why the minimal discount matters

Small companies can sometimes be forced to offer substantial discounts when raising fresh equity. Zenith's approximate 0.36% discount is therefore one of the more encouraging features of this announcement.

It suggests the participating institutional investors were prepared to fund the company at close to the prevailing Oslo market price. Existing shareholders who did not participate were diluted, but the company did not issue the shares at a heavily reduced valuation.

Management argues that a wider offer to existing shareholders would have taken longer, cost more and created greater exposure to market volatility and execution risk. The board says the private placement was an efficient and timely way to secure capital with a high degree of certainty.

That explanation is reasonable on its own terms, although non-participating retail shareholders still had no opportunity through this financing to preserve their percentage ownership.

The warrants are the main catch

Each new share came with one warrant, giving the holder the right to buy another Zenith share for NOK 0.675 during the next two years.

A warrant is an instrument that allows its holder to subscribe for a new share at a fixed price before an expiry date. If all 50 million warrants are exercised, Zenith's share count would rise from 764,756,457 to 814,756,457, assuming no other changes.

Full exercise would generate approximately NOK 33.75 million in additional funding, equivalent to roughly £2.595 million using the sterling exercise-price figure disclosed by Zenith. That cash is not guaranteed because warrant holders will normally exercise only if it makes economic sense at the time.

For existing investors, the trade-off is straightforward. Exercise could bring more capital into the business without another fundraising process, but it would also dilute shareholders again.

The warrants may also create an overhang. If Zenith's market price rises above the exercise price, investors will know that another 50 million shares could enter circulation.

Where will the money go?

Zenith has identified four broad uses for the financing proceeds:

1. Due diligence and construction funding for the new biogas project announced on the previous day.
2. Additional funding for legal expenses linked to international arbitration proceedings initiated by its wholly owned subsidiaries.
3. Continued development of the solar energy portfolio, including construction at certain ready-to-build sites.
4. General working capital.

This is a wide spread of demands on a £2.116 million raise. The financing is not being directed towards one fully defined asset or construction programme, and the RNS does not disclose how much will be allocated to each category.

The inclusion of general working capital also matters. It means some of the cash may support everyday corporate requirements rather than directly creating new operating capacity.

Similarly, legal expenses can be strategically important, particularly where arbitration claims might carry potential value, but they consume cash without guaranteeing a successful financial outcome. Zenith did not disclose the expected remaining cost, timetable or potential recovery from the proceedings in this announcement.

Biogas and solar remain central to the growth case

Chief executive Andrea Cattaneo said Zenith's solar portfolio is approaching a 200 MWp development pipeline. MWp means megawatt-peak, a measure of a solar project's maximum rated generating capacity under standard conditions.

The company also said construction of its first solar energy production facility began in July 2026. Zenith intends to move additional ready-to-build projects into construction and production, although it may monetise certain projects depending on market conditions.

The financing therefore buys Zenith additional capacity to advance its renewable energy plans, but it is not enough on its own to demonstrate that the wider pipeline will be built or become cash-generative.

Important details such as expected construction expenditure, project-level economics, completion dates and anticipated revenue were not disclosed in this RNS.

The new biogas project is another potential use of capital, but this announcement provides no further detail on its size, ownership structure, economics or development timetable beyond the proposed due diligence and construction funding.

What looks positive for shareholders?

The strongest feature is the pricing. Raising approximately £2.116 million at a discount of only 0.36% limits the value transferred to incoming investors through the initial share issue.

Existing institutional investors participated, and the company has secured funds for several areas that management regards as strategically important. The financing should also provide near-term support for the balance sheet and working-capital position.

If the solar and biogas projects progress towards production or monetisation, the capital could help Zenith turn development opportunities into tangible assets or cash proceeds.

What should investors watch?

Dilution is the first issue. There are now 50 million additional shares, with a further 50 million potentially issuable through the warrants.

The second issue is funding sufficiency. Zenith is dividing the proceeds between project development, construction, legal costs and working capital. The announcement does not say how long the new cash is expected to last or whether further financing will be required.

Investors should also distinguish between pipeline size and operating output. A solar development pipeline approaching 200 MWp may indicate opportunity, but it does not mean that capacity is financed, constructed or generating revenue.

Future updates will need to show how the £2.116 million is allocated, whether ready-to-build solar sites move into construction, what emerges from biogas due diligence and how arbitration-related costs develop.

Fresh cash buys progress, not certainty

Zenith has secured capital at close to the previous market price, which is a better outcome than a deeply discounted placing. The funding gives management more room to advance its renewable projects and meet legal and working-capital requirements.

The price is a larger share count today and the possibility of further dilution over the next two years. For shareholders, the key question is now whether Zenith can convert this fresh capital into measurable project progress before it needs to return to the market for more money.